CytomX Therapeutics, Inc. (CTMX)


+0.01 (+0.55%)
Symbol CTMX
Price $1.84
Beta 0.762
Volume Avg. 1.09M
Market Cap 120.333M
Shares () -
52 Week Range 1.505-7.53
1y Target Est -
DCF Unlevered CTMX DCF ->
DCF Levered CTMX LDCF ->
ROE -91.89% Strong Sell
ROA -30.97% Strong Sell
Operating Margin -
Debt / Equity 335.27% Strong Buy
P/E -
P/B 1.76 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest CTMX news

DR. Sean McCarthy
NASDAQ Global Select

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.